Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Caribou Biosciences Inc (CRBU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Caribou Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.830 +0.060    +1.59%
21:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
3.970
+0.140
+3.655%
21:58:22 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,572,011
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.760 - 3.928
Caribou Biosciences 3.830 +0.060 +1.59%

Caribou Biosciences Inc Company Profile

 
Get an in-depth profile of Caribou Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

137

Equity Type

ORD

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Contact Information

Address 2929 7th Street Suite 105
Berkeley, 94710
United States
Phone 510 982 6030
Fax -

Top Executives

Name Age Since Title
Rachel E. Haurwitz 36 2011 Co-Founder, CEO, President & Director
Martin Jinek - - Member of Scientific Advisory Board
Andrew L. Guggenhime 54 2021 Independent Chairman
Katy Rezvani - - Member of Scientific Advisory Board
Scott N. Braunstein 59 2021 Independent Director
Jennifer A. Doudna 58 - Member of Scientific Advisory Board
Cameron J. Turtle - - Member of Scientific Advisory Board
Natalie R. Sacks 57 2018 Independent Director
Noopur Raje - - Member of Scientific Advisory Board
Dara Richardson-Heron 59 2021 Independent Director
Ami Bhatt - - Member of Scientific Advisory Board
Ran Zheng 59 2021 Independent Director
Nancy Whiting 50 2021 Independent Director
David Lee Johnson 54 2022 Independent Director
Stephen J. Schuster - 2023 Member of Scientific Advisory Board
Sundar Jagannath - 2023 Member of Scientific Advisory Board
Akos Czibere - 2024 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CRBU Comments

Write your thoughts about Caribou Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email